Table 3

 Mean change in HRQoL domains over 12 months related to baseline disease duration

Disease duration (years)TreatmentPFRPBPGHVTSFREMHPCSMCSHAQFatigue
Treatment groups are “Abatacept” = abatacept + MTX and “Placebo” = placebo + MTX.
PF, physical functioning; RP, role physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role emotional; MH, mental health; PCS, physical component summary; MCS, mental component summary.
*p<0.001; †p<0.01; ‡p<0.05; §p<0.1.
⩽2Abatacept8.85 (1.09)9.03 (1.24)9.72 (1.01)5.64 (0.85)7.78 (1.03)6.58 (1.16)7.77 (1.56)6.69 (1.11)8.62 (0.94)6.04 (1.15)−0.74 (0.06)−23.79 (2.87)
Placebo4.73 (1.69)7.42 (1.93)5.78 (1.58)5.78 (1.32)5.54 (1.60)6.62 (1.81)6.42 (2.42)3.37 (1.72)6.02 (1.46)4.85 (1.79)−0.38 (0.10)−16.37 (4.45)
>2–5Abatacept8.40 (1.13)11.40 (1.30)14.28 (1.06)6.02 (0.89)7.78 (1.07)8.71 (1.21)11.35 (1.62)6.59 (1.16)10.13 (0.98)7.48 (1.20)−0.76 (0.07)−26.92 (2.99)
Placebo4.79 (1.63)4.45 (1.86)5.19 (1.52)2.52(1.28)3.87 (1.54)3.82 (1.74)4.79 (2.34)3.54 (1.66)4.25 (1.41)3.54 (1.73)−0.38 (0.10)−19.82 (4.30)
>5–10Abatacept8.54 (1.06)9.73 (1.23)11.97 (1.00)6.63 (0.84)8.40 (1.02)9.24 (1.15)6.99 (1.54)6.53 (1.09)9.89 (0.93)6.23 (1.14)−0.63 (0.06)−25.34 (2.84)
Placebo5.96 (1.53)8.06 (1.75)7.07 (1.42)4.42 (1.20)6.01 (1.45)7.16 (1.64)8.53 (2.19)7.70 (1.56)5.49 (1.32)7.66 (1.62)−0.38 (0.09)−18.84 (4.03)
>10Abatacept6.39 (0.94)7.89 (1.07)10.34 (0.88)7.39 (0.73)8.30 (0.89)8.49 (1.00)7.68 (1.34)5.94 (0.96)8.00 (0.81)6.89 (0.99)−0.53 (0.06)−26.66 (2.47)
Placebo3.79 (1.27)4.46 (1.45)6.36 (1.18)4.48 (0.99)4.32 (1.20)5.06 (1.35)5.92 (1.81)2.19 (1.29)4.78 (1.09)3.90 (1.34)−0.39 (0.08)−15.96 (3.34)
F -statistic—disease duration1.241.451.111.000.410.710.212.020.560.590.970.28
F-statistic—treatment11.95*10.23†39.50*8.41†12.51*6.72†2.305.51‡24.83*2.84§25.76*10.38†
F-statistic—interaction0.171.241.861.080.290.991.461.500.741.421.180.18